Zonisamide in the management of epilepsy in the elderly

Research output: Contribution to journalArticlepeer-review


Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe. Evidence on the efficacy and tolerability of antiepileptic drugs in the elderly is still lacking as these patients are frequently excluded from clinical trials. Here, a comprehensive overview of available data regarding the use of ZNS in the treatment of epilepsy in elderly people is provided. In a pooled analysis conducted in patients aged ≥65 years, no new/unexpected safety findings have emerged. Few data from uncontrolled investigations suggest that ZNS may be effective and well tolerated when administered as monotherapy or adjunctive antiepileptic treatment in the elderly. However, evidence from these observational studies is less than satisfactory, and randomized controlled trials focused on these patients are still needed.

Original languageEnglish
Pages (from-to)931-937
Number of pages7
JournalClinical Interventions in Aging
Publication statusPublished - Jun 8 2015


  • Efficacy
  • Elderly
  • Epilepsy
  • Safety
  • Zonisamide

ASJC Scopus subject areas

  • Geriatrics and Gerontology


Dive into the research topics of 'Zonisamide in the management of epilepsy in the elderly'. Together they form a unique fingerprint.

Cite this